Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

Emergence of Novel Norovirus GII.4 Variant.
Chhabra, P; TULLY, DC; Mans, J; Niendorf, S; Barclay, L; Cannon, JL; Montmayeur, AM; Pan, C-Y; Page, N; Williams, R; Tutill, H; Roy, S; Celma, C; Beard, S; Mallory, ML; Manouana, GP; Velavan, TP; Adegnika, AA; Kremsner, PG; Lindesmith, LC; Hué, S; Baric, RS; Breuer, J; Vinjé, J;
2023
Emerging infectious diseases, (2023).30 1 10.3201/eid3001.231003.
epidemery/subclinical_transmission.
Emery, JC; Dodd, PJ; Banu, S; Frascella, B; Garden, FL; HORTON, KC; Hossain, S; Law, I; Van Leth, F; Marks, GB; Nguyen, HB; Nguyen, HV; Onozaki, I; Quelapio, MI D; RICHARDS, AS; Shaikh, N; Tiemersma, EW; WHITE, RG; Zaman, K; Cobelens, F; HOUBEN, RM G J;
2023
, GitHub (2023).
Vaccine value profile for Chikungunya.
Flandes, X; Hansen, CA; Palani, S; ABBAS, K; Bennett, C; Caro, WP; Hutubessy, R; Khazhidinov, K; Lambach, P; Maure, C; Marshall, C; Rojas, DP; Rosewell, A; Sahastrabuddhe, S; Tufet, M; Wilder-Smith, A; Beasley, DW C; Bourne, N; Barrett, AD T;
2023
Vaccine, (2023).42 19S1 10.1016/j.vaccine.2023.07.069.
The Full Value of Vaccine Assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making.
Hutubessy, R; Lauer, JA; Giersing, B; Sim, SY; JIT, M; Kaslow, D; Botwright, S;
2023
BMC medicine, (2023).21 1 10.1186/s12916-023-02929-0.
Programmatic considerations for chikungunya vaccine introduction in countries at risk of chikungunya outbreaks: stakeholder analysis.
AUZENBERGS, M; Maure, C; KANG, H; BRADY, O; Sahastrabuddhe, S; Abbas, K;
2023
medRxiv (2023). 10.1101/2023.09.26.23296129.
The potential cost-effectiveness of next generation influenza vaccines in England and Wales: A modelling analysis.
WATERLOW, NR; PROCTER, SR; VAN LEEUWEN, E; Radhakrishnan, S; JIT, M; EGGO, RM;
2023
Vaccine, (2023).41 41 10.1016/j.vaccine.2023.08.031.
Challenges and opportunities in developing a Shigella-containing combination vaccine for children in low- and middle-income countries: Report of an expert convening.
Riddle, MS; Louis Bourgeois, A; Clifford, A; Jeon, S; Giersing, BK; JIT, M; Tufet Bayona, M; Ovitt, J; Hausdorff, WP;
2023
Vaccine, (2023).41 16 10.1016/j.vaccine.2023.03.003.
The impact of Long COVID on Health-Related Quality-of-Life using OpenPROMPT.
CARLILE, O; BRIGGS, A; Henderson, A; Butler-Cole, BF C; TAZARE, J; TOMLINSON, L; MARKS, M; JIT, M; LIN, L-Y; Bates, C; Parry, J; Bacon, SC J; Dillingham, I; Dennison, W; COSTELLO, R; Walker, A; Hulme, W; GOLDACRE, B; Mehrkar, A; MacKenna, B; The OpenSAFELY Collaborative,; HERRETT, E; EGGO, R;
2023
medRxiv (2023). 10.1101/2023.12.06.23299601.
Recent Travel and Tuberculosis in Migrants: Data From a Low-Incidence Country.
SCHWALB, A; Kayumba, K; HOUBEN, RM G J; Bothamley, GH;
2023
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, (2023).78 3 10.1093/cid/ciad672.
Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data.
Feng, S; McLellan, J; Pidduck, N; Roberts, N; Higgins, JP T; Choi, Y; Izu, A; JIT, M; Madhi, SA; Mulholland, K; Pollard, AJ; Temple, B; Voysey, M;
2023
EClinicalMedicine, (2023).61, 10.1016/j.eclinm.2023.102073.